120 related articles for article (PubMed ID: 38798040)
1. Impact of comorbidities on prostate cancer-specific mortality: A population-based cohort study.
Tiruye T; Roder D; FitzGerald LM; O'Callaghan M; Moretti K; Caughey GE; Beckmann K
Prostate; 2024 May; ():. PubMed ID: 38798040
[TBL] [Abstract][Full Text] [Related]
2. Medication-based Comorbidity Measures and Prostate Cancer Treatment Selection.
Tiruye T; O'Callaghan M; FitzGerald LM; Moretti K; Jay A; Higgs B; Kichenadasse G; Caughey G; Roder D; Beckmann K
Clin Genitourin Cancer; 2024 Apr; 22(2):599-609.e2. PubMed ID: 38369388
[TBL] [Abstract][Full Text] [Related]
3. Utility of prescription-based comorbidity indices for predicting mortality among Australian men with prostate cancer.
Tiruye T; Roder D; FitzGerald LM; O'Callaghan M; Moretti K; Beckmann K
Cancer Epidemiol; 2024 Feb; 88():102516. PubMed ID: 38141473
[TBL] [Abstract][Full Text] [Related]
4. Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: an Australian population-based cohort study.
Ng HS; Koczwara B; Roder D; Vitry A
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):403-410. PubMed ID: 29720722
[TBL] [Abstract][Full Text] [Related]
5. Patterns of comorbidities in women with breast cancer: a Canadian population-based study.
Ng HS; Vitry A; Koczwara B; Roder D; McBride ML
Cancer Causes Control; 2019 Sep; 30(9):931-941. PubMed ID: 31280456
[TBL] [Abstract][Full Text] [Related]
6. Contribution of an extensive medication-based comorbidity index (Rx-Risk) in explaining the excess mortality after hip fracture in older Norwegians: a NOREPOS cohort study.
Holvik K; Hjellvik V; Karlstad Ø; Gunnes N; Hoff M; Tell GS; Meyer HE
BMJ Open; 2022 May; 12(5):e057823. PubMed ID: 35501100
[TBL] [Abstract][Full Text] [Related]
7. Does a Prescription-based Comorbidity Index Correlate with the American Society of Anesthesiologists Physical Status Score and Mortality After Joint Arthroplasty? A Registry Study.
Kerr MM; Graves SE; Duszynski KM; Inacio MC; de Steiger RN; Harris IA; Ackerman IN; Jorm LR; Lorimer MF; Gulyani A; Pratt NL
Clin Orthop Relat Res; 2021 Oct; 479(10):2181-2190. PubMed ID: 34232146
[TBL] [Abstract][Full Text] [Related]
8. Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer.
Daskivich TJ; Fan KH; Koyama T; Albertsen PC; Goodman M; Hamilton AS; Hoffman RM; Stanford JL; Stroup AM; Litwin MS; Penson DF
Ann Intern Med; 2013 May; 158(10):709-17. PubMed ID: 23689764
[TBL] [Abstract][Full Text] [Related]
9. Socioeconomic disadvantage but not remoteness affects short-term survival in prostate cancer: A population-based study using competing risks.
Thomas AA; Pearce A; Sharp L; Gardiner RA; Chambers S; Aitken J; Molcho M; Baade P
Asia Pac J Clin Oncol; 2017 Apr; 13(2):e31-e40. PubMed ID: 27558311
[TBL] [Abstract][Full Text] [Related]
10. The validity of the Rx-Risk Comorbidity Index using medicines mapped to the Anatomical Therapeutic Chemical (ATC) Classification System.
Pratt NL; Kerr M; Barratt JD; Kemp-Casey A; Kalisch Ellett LM; Ramsay E; Roughead EE
BMJ Open; 2018 Apr; 8(4):e021122. PubMed ID: 29654048
[TBL] [Abstract][Full Text] [Related]
11. Psychiatric comorbidity and risk of premature mortality and suicide among those with chronic respiratory diseases, cardiovascular diseases, and diabetes in Sweden: A nationwide matched cohort study of over 1 million patients and their unaffected siblings.
Sariaslan A; Sharpe M; Larsson H; Wolf A; Lichtenstein P; Fazel S
PLoS Med; 2022 Jan; 19(1):e1003864. PubMed ID: 35085232
[TBL] [Abstract][Full Text] [Related]
12. Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality.
Dess RT; Hartman HE; Mahal BA; Soni PD; Jackson WC; Cooperberg MR; Amling CL; Aronson WJ; Kane CJ; Terris MK; Zumsteg ZS; Butler S; Osborne JR; Morgan TM; Mehra R; Salami SS; Kishan AU; Wang C; Schaeffer EM; Roach M; Pisansky TM; Shipley WU; Freedland SJ; Sandler HM; Halabi S; Feng FY; Dignam JJ; Nguyen PL; Schipper MJ; Spratt DE
JAMA Oncol; 2019 Jul; 5(7):975-983. PubMed ID: 31120534
[TBL] [Abstract][Full Text] [Related]
13. Association of pre-existing comorbidities with mortality and disease severity among 167,500 individuals with COVID-19 in Canada: A population-based cohort study.
Ge E; Li Y; Wu S; Candido E; Wei X
PLoS One; 2021; 16(10):e0258154. PubMed ID: 34610047
[TBL] [Abstract][Full Text] [Related]
14. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
[TBL] [Abstract][Full Text] [Related]
15. Comorbidities, treatment and ensuing survival in men with prostate cancer.
Chamie K; Daskivich TJ; Kwan L; Labo J; Dash A; Greenfield S; Litwin MS
J Gen Intern Med; 2012 May; 27(5):492-9. PubMed ID: 21935751
[TBL] [Abstract][Full Text] [Related]
16. Mortality Risks Associated with Depression in Men with Prostate Cancer.
Crump C; Stattin P; Brooks JD; Sundquist J; Sieh W; Sundquist K
Eur Urol Oncol; 2024 Apr; ():. PubMed ID: 38575410
[TBL] [Abstract][Full Text] [Related]
17. Differences according to socioeconomic status in the management and mortality in men with high risk prostate cancer.
Berglund A; Garmo H; Robinson D; Tishelman C; Holmberg L; Bratt O; Adolfsson J; Stattin P; Lambe M
Eur J Cancer; 2012 Jan; 48(1):75-84. PubMed ID: 21852113
[TBL] [Abstract][Full Text] [Related]
18. The role of multimorbidity in short-term mortality of lung cancer patients in Spain: a population-based cohort study.
Niksic M; Redondo-Sanchez D; Chang YL; Rodriguez-Barranco M; Exposito-Hernandez J; Marcos-Gragera R; Oliva-Poch E; Bosch-Barrera J; Sanchez MJ; Luque-Fernandez MA
BMC Cancer; 2021 Sep; 21(1):1048. PubMed ID: 34556072
[TBL] [Abstract][Full Text] [Related]
19. Risk of cardiovascular mortality with androgen deprivation therapy in prostate cancer: A secondary analysis of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Randomized Controlled Trial.
Butler SS; Mahal BA; Moslehi JJ; Nohria A; Dee EC; Makkar R; Whitbeck A; Wangoe J; Mouw KW; Nguyen PL; Muralidhar V
Cancer; 2021 Jul; 127(13):2213-2221. PubMed ID: 33905530
[TBL] [Abstract][Full Text] [Related]
20. Matching tumor risk with aggressiveness of treatment in men with multiple comorbidities and early-stage prostate cancer.
Daskivich TJ; Chamie K; Kwan L; Dash A; Greenfield S; Litwin MS
Cancer; 2013 Oct; 119(19):3446-53. PubMed ID: 23861016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
